|
|
CSL Behring Receives Canadian Notice of Compliance for Berinert®
Berinert is now the first and only licensed treatment in Canada for acute episodes of Hereditary Angioedema, a rare and potentially fatal genetic disorder
Ottawa, Canada — 06/01/2010
CSL Behring Canada announced today that it has received Notice of Compliance for Berinert® (Human C1 Esterase Inhibitor). The company may now market Berinert for the treatment of acute abdominal or facial attacks of hereditary angioedema (HAE) of moderate and severe intensity. HAE is a rare and serious genetic disorder.
More 
|